Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Elizabeth Hedgeman, EpidStrategies
  • ,
  • Mette Nørgaard, Hospital Pharmacy, Aarhus University Hospital, Aarhus
  • ,
  • Tapashi Dalvi, Astraallen, AstraZeneca, AstraZeneca Nord Balt
  • ,
  • Lars Pedersen
  • Hanh Pham Hansen, Hospital Pharmacy, Aarhus University Hospital, Aarhus
  • ,
  • Jill Walker, Astraallen, AstraZeneca, AstraZeneca Nord Balt
  • ,
  • Anita Midha, Astraallen, AstraZeneca, AstraZeneca Nord Balt
  • ,
  • Norah Shire, Astraallen, AstraZeneca, AstraZeneca Nord Balt
  • ,
  • Anne-Marie Boothman, Astraallen, AstraZeneca, AstraZeneca Nord Balt
  • ,
  • Jon P Fryzek, Hospital Pharmacy, Aarhus University Hospital, Aarhus
  • ,
  • James Rigas, Astraallen, AstraZeneca, AstraZeneca Nord Balt
  • ,
  • Anders Mellemgaard, Bornholms Hospital
  • ,
  • Torben R Rasmussen
  • Stephen Hamilton-Dutoit
  • Deirdre Cronin-Fenton

BACKGROUND: PD-L1 expression on tumor cells (TCs) or immune cells (ICs) may be used as a prognostic marker for survival in patients with NSCLC. We characterized PD-L1 expression on TCs or ICs in a patient cohort with NSCLC to determine associations between PD-L1 expression and overall survival (OS), according to EGFR and KRAS mutation status.

METHODS: Danish patients aged >18 years diagnosed with NSCLC before 2014 on first- (N = 491), second- (N = 368), or third-line (N = 498) therapy were included. Data were extracted from population-based medical registries. Tumor samples from pathology archives were tested for biomarkers. High PD-L1 expression was defined as expression on ≥25 % of TCs or ICs based on first diagnostic biopsy or surgical resection. KRAS and EGFR mutation status were tested using PCR-based assays. Cox regression analysis was used to compute adjusted HRs and associated 95 % CIs.

RESULTS: PD-L1 TC and IC ≥ 25 % were observed in 24.3 %-31.0 % and 11.7-14.7 % of patients, respectively. EGFR and KRAS mutations were detected in 4.7 %-8.8 % and 26.5 %-30.7 % of patients, respectively. PD-L1 TC ≥ 25 % was not associated with survival advantage in first- (HR = 0.96, 95 % CI: 0.75-1.22), second- (1.08, 0.81-1.42), or third-line (0.94, 0.74-1.20) therapy. PD-L1 IC ≥ 25 % was associated with survival advantage in second-line (HR = 0.56, 95 % CI: 0.36-0.86) and third-line (0.69, 0.49-0.97) but not first-line (1.00, 0.70-1.41) therapy.

CONCLUSION: No association was observed between PD-L1 TC ≥ 25 % and OS in any therapy line. PD-L1 IC ≥ 25 % may confer survival benefit among some patients who reach second-line therapy.

OriginalsprogEngelsk
TidsskriftCancer epidemiology
Vol/bind73
Sider (fra-til)101976
ISSN1877-7821
DOI
StatusE-pub ahead of print - 1 jul. 2021

Bibliografisk note

Copyright © 2021. Published by Elsevier Ltd.

Se relationer på Aarhus Universitet Citationsformater

ID: 219403108